MedWatch

Oticon Foundation in large cancer therapy venture

The Oticon Foundation's investment arm, William Demant Invest, is buying 85 percent of shares in a large international medtech company that produces equipment for cancer diagnostics. "In our context, it is a significant acquisition," says CEO Niels Jacobsen.

Niels Jacobsen stepped down as CEO of William Demant Holding in 2017 after 25 years on the post. Since then he has been in charge of William Demant Invest.

The Danish investment company William Demant Invest, 100 percent owned by the Oticon Foundation, which sits on the share majority in the hearing aid group William Demant has just announced that it is acquiring the UK and international company Vision RT that produces products for radiation treatment of cancer tumors. 

William Demant Invest will take over 85 percent of the company, while the three founders maintain an ownership stake.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier